基于材料学改善冠状动脉旁路移植术后移植静脉再狭窄的研究进展

Research progress of vein graft restenosis after coronary artery bypass grafting based on material science

移植静脉再狭窄严重影响冠状动脉旁路移植术患者预后。临床术后常规药物对缓解移植静脉的内膜增生疗效甚微,且血管外支架及内膜载药材料均存在力学及生物性质的不可控,是目前移植静脉再狭窄研究的瓶颈。随着材料学发展,具备组织相容性好、细胞毒性小、理化性质可控的载药材料逐渐可以满足移植静脉再狭窄防治的需求,通过医学与材料化学的跨领域交叉与协作,寻找合适的载药材料,对提高冠状动脉旁路移植术后移植静脉远期通畅率具有极其重要的意义。本文对近年来基于材料学改善冠状动脉旁路移植术后移植静脉再狭窄的相关治疗进展作简要综述。

Restenosis of vein graft seriously affects the prognosis of coronary artery bypass grafting.Conventional medicationis insufficient in reducing intimal hyperplasia of vein graftafter surgery.Mechanical and biological properties of external stent and drug carrier materials are uncontrollable.With the development of material science,drug carrier materials with good histocompatibility,low cytotoxicity,controllable physical and chemical properties can be used in prevention and treatment of vein graft restenosis.It is of great significance to find suitable drug carrier materials through cross-disciplinary interaction and collaboration between medicine and material chemistry,so as to improve the long-term patency rate of vein graft after coronary artery bypass grafting.This paper reviewed the progress in treatment of vein graft restenosis after coronary artery bypass grafting based on material science.